Genetic Loci Associated with Alzheimer's Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Elias Sonnenschein, Lyzel S ^a   Helisalmi, Seppo ^b   Natunen, Teemu ^b   Hall, Anette ^b   Paajanen, Teemu ^b,e   Herukka, Sanna Kaisa ^b   Laitinen, Marjo ^b   Remes, Anne M ^b   Koivisto, Anne M ^b   Mattila, Kari M ^c   Lehtimäki, Terho ^c   Verhey, Frans R J ^a   Visser, Pieter Jelle ^a,d   Soininen, Hilkka ^b   Hiltunen, Mikko ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CLUSTERIN; MEMBRANE PROTEIN; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 40 HOMOLOG; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FINLAND; GENDER; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CLUSTERIN; FEMALE; FINLAND; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK FACTORS; TAU PROTEINS;

EID: 84875711900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059676     Document Type: Article

References (49)

1. Blennow K, de Leon MJ, Zetterberg H, (2006) Alzheimer's disease. Lancet 368: 387-403.
2. Bu G, (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10: 333-344.
3. Bekris LM, Millard S, Lutz F, Li G, Galasko DR, et al. (2012) Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 159B: 874-883.
4. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, et al. (2010) SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6.
5. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT, (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32: 150-159.
6. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519.
7. Lambert JC, Amouyel P, (2011) Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr Opin Genet Dev 21: 295-301.
8. Bertram L, Lill CM, Tanzi RE, (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270-281.
9. Elias-Sonnenschein LS, Bertram L, Visser PJ, (2012) Relationship between genetic risk factors and markers for Alzheimer's disease pathology. Biomark Med 6: 477-495.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
11. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE, (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23.
12. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90: 1977-1981.
13. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349-1356.
14. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol.
15. Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A, (2011) Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis 2011: 832379.
16. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43: 429-435.
17. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-1840.
18. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43: 436-441.
19. Han MR, Schellenberg GD, Wang LS, (2010) Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study. BMC Neurol 10: 90.
20. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, et al. (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76: 69-79.
21. Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, et al. (2011) Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 32: 2113-2122.
22. Iivonen S, Corder E, Lehtovirta M, Helisalmi S, Mannermaa A, et al. (2004) Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology 62: 1170-1176.
23. Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, et al. (2009) Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 10: 13-17.
24. Helisalmi S, Vepsalainen S, Koivisto AM, Mannermaa A, Iivonen S, et al. (2006) Association of CYP46 intron 2 polymorphism in Finnish Alzheimer's disease samples and a global scale summary. J Neurol Neurosurg Psychiatry 77: 421-422.
25. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, et al. (2004) Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet 114: 581-587.
26. Vepsalainen S, Helisalmi S, Mannermaa A, Pirttila T, Soininen H, et al. (2009) Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 1268-1270.
27. Vepsalainen S, Parkinson M, Helisalmi S, Mannermaa A, Soininen H, et al. (2007) Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J Med Genet 44: 606-608.
28. Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, et al. (2005) Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging 26: 795-802.
29. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
30. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, et al. (2011) Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging 32: 756 e711-755.
31. Vepsalainen S, Castren E, Helisalmi S, Iivonen S, Mannermaa A, et al. (2005) Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer's disease. J Neurol 252: 423-428.
32. Purcell S, Cherny SS, Sham PC, (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150.
33. Lenth RV (2006-9) Java Applets for Power and Sample Size.
34. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57: 289-300.
35. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
36. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, et al. (2012) Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region. Arch Neurol: 1-10.
37. Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, et al. (2010) Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J Alzheimers Dis 21: 833-842.
38. Schott JM (2011) Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. Neurobiol Aging.
39. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, et al. (2011) The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 68: 207-213.
40. Rosenthal SL, Wang X, Demirci FY, Barmada MM, Ganguli M, et al. (2012) Beta-Amyloid Toxicity Modifier Genes and the Risk of Alzheimer's Disease. Am J Neurodegener Dis 1: 191-198.
41. Schmidt C, Wolff M, von Ahsen N, Zerr I, (2012) Alzheimer's disease: genetic polymorphisms and rate of decline. Dement Geriatr Cogn Disord 33: 84-89.
42. Karch CM, Jeng AT, Goate AM (2012) Calcium phosphatase calcineurin influences tau metabolism. Neurobiol Aging.
43. Reese LC, Taglialatela G, (2011) A role for calcineurin in Alzheimer's disease. Curr Neuropharmacol 9: 685-692.
44. Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, et al. (2011) Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol 68: 99-106.
45. Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, et al. (2011) Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement Geriatr Cogn Disord 32: 164-170.
46. Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, et al. (2008) Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett 440: 68-71.
47. Olgiati P, Politis A, Albani D, Rodilossi S, Polito L, et al. (2012) Association of SORL1 alleles with late-onset Alzheimer's disease. findings from the GIGAS_LOAD study and mega-analysis. Curr Alzheimer Res 9: 491-499.
48. Cuenco KT, Lunetta KL, Baldwin CT, McKee AC, Guo J, et al. (2008) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 65: 1640-1648.
49. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, et al. (2008) Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A 105: 8050-8054.